MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders... Show more
Industry Biotechnology
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| SOFA | 12.24 | 0.31 | +2.62% |
| Direxion Daily SOFI Bull 2X ETF (SOFA) | |||
| SPLS | 55.21 | 0.11 | +0.20% |
| PIMCO US Stocks PLUS Active Bond Exchange-Traded Fund (SPLS) | |||
| XYLD | 41.72 | 0.03 | +0.07% |
| Global X S&P 500 Covered Call ETF (XYLD) | |||
| CFA | 97.45 | -0.38 | -0.39% |
| VictoryShares US 500 Volatility Wtd ETF (CFA) | |||
| FRGN | 31.45 | -0.25 | -0.78% |
| Horizon International Equity ETF (FRGN) | |||
A.I.dvisor indicates that over the last year, MBX has been loosely correlated with KOD. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if MBX jumps, then KOD could also see price increases.
| Ticker / NAME | Correlation To MBX | 1D Price Change % | ||
|---|---|---|---|---|
| MBX | 100% | -1.53% | ||
| KOD - MBX | 41% Loosely correlated | -0.43% | ||
| CNTN - MBX | 37% Loosely correlated | +9.52% | ||
| IMVT - MBX | 33% Loosely correlated | -1.86% | ||
| TGTX - MBX | 33% Loosely correlated | +0.71% | ||
| SION - MBX | 33% Poorly correlated | -16.99% | ||
More | ||||
On September 16, 2026, the Stochastic Oscillator for MBX moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 25 instances where the indicator left the oversold zone. In 23 of the 25 cases the stock moved higher in the following days. This puts the odds of a move higher at over 90%.
The Momentum Indicator moved above the 0 level on September 16, 2026. You may want to consider a long position or call options on MBX as a result. In 23 of 28 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
Following a +4.60% 3-day Advance, the price is estimated to grow further. Considering data from situations where MBX advanced for three days, in 117 of 124 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
MBX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
MBX moved below its 50-day moving average on September 18, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for MBX crossed bearishly below the 50-day moving average on September 09, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 3 of 5 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 60%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MBX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for MBX entered a downward trend on September 18, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 24 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. MBX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 58 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.396) is normal, around the industry mean (25.929). P/E Ratio (3.877) is within average values for comparable stocks, (40.079). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.178). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (437.043).
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MBX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.